Mark C. Schneyer Acadia Pharmaceuticals Inc (ACAD) insider trading activity

Mark C. Schneyer is EVP, CHIEF FINANCIAL OFFICER of ACADIA PHARMACEUTICALS INC. Currently has a direct ownership of 53,302 shares of ACAD, which is worth approximately $885,346. The most recent transaction as insider was on Nov 19, 2024, when has been sold 10,259 shares (Common Stock) at a price of $16.81 per share, resulting in proceeds of $172,453. This information was disclosed in a Form 4 filing with the Securities and Exchange Commission (SEC).

Shares Held (Direct Ownership) 53.3K

21.87% 3M change

160.19% 12M change

Total Value Held $885,346

Mark C. Schneyer Transaction History

Date	Transaction	Value	Shares Traded	Shares Held
Nov 19 2024	SELL Open market or private sale	$172,453 $16.81 p/Share	10,259 Reduced 16.14%	53,302 Common Stock
Nov 17 2024	BUY Exercise of conversion of derivative security	-	19,826 Added 23.78%	63,561 Common Stock
Aug 19 2024	SELL Open market or private sale	$148,720 $15.28 p/Share	9,733 Reduced 18.2%	43,735 Common Stock
Aug 16 2024	BUY Grant, award, or other acquisition	-	18,904 Added 26.12%	53,468 Common Stock
Jun 10 2024	SELL Open market or private sale	$14,420 $14.79 p/Share	975 Reduced 2.74%	34,564 Common Stock
Jun 08 2024	BUY Exercise of conversion of derivative security	-	1,893 Added 5.06%	35,539 Common Stock
May 02 2024	SELL Open market or private sale	$59,340 $16.94 p/Share	3,503 Reduced 9.85%	32,053 Common Stock
May 01 2024	BUY Exercise of conversion of derivative security	-	6,814 Added 16.08%	35,556 Common Stock
Apr 08 2024	SELL Open market or private sale	$48,534 $17.87 p/Share	2,716 Reduced 8.63%	28,742 Common Stock
Apr 05 2024	BUY Exercise of conversion of derivative security	-	5,275 Added 14.36%	31,458 Common Stock
Mar 27 2024	SELL Open market or private sale	$97,268 $17.9 p/Share	5,434 Reduced 17.19%	26,183 Common Stock
Mar 25 2024	BUY Grant, award, or other acquisition	-	10,550 Added 25.02%	31,617 Common Stock
Feb 26 2024	SELL Open market or private sale	$19,045 $24.67 p/Share	772 Reduced 3.53%	21,067 Common Stock
Feb 23 2024	BUY Exercise of conversion of derivative security	-	1,353 Added 5.83%	21,839 Common Stock
Nov 20 2023	SELL Open market or private sale	$115,645 $22.64 p/Share	5,108 Reduced 19.96%	20,486 Common Stock
Nov 17 2023	BUY Exercise of conversion of derivative security	-	9,912 Added 27.92%	25,594 Common Stock
Aug 21 2023	SELL Open market or private sale	$290,000 $29.0 p/Share	10,000 Reduced 38.94%	15,682 Common Stock
Jun 08 2023	SELL Open market or private sale	$24,369 $25.02 p/Share	974 Reduced 4.09%	22,824 Common Stock
Jun 08 2023	BUY Exercise of conversion of derivative security	-	1,893 Added 7.37%	23,798 Common Stock
May 17 2023	SELL Open market or private sale	$344,475 $22.5 p/Share	15,310 Reduced 41.14%	21,905 Common Stock
May 17 2023	BUY Exercise of conversion of derivative security	-	29,738 Added 44.42%	37,215 Common Stock
Apr 06 2023	SELL Open market or private sale	$34,794 $18.16 p/Share	1,916 Reduced 20.4%	7,477 Common Stock
Apr 05 2023	BUY Exercise of conversion of derivative security	-	5,275 Added 35.96%	9,393 Common Stock
Feb 24 2023	SELL Open market or private sale	$10,836 $18.78 p/Share	577 Reduced 12.29%	4,118 Common Stock
Feb 23 2023	BUY Exercise of conversion of derivative security	-	1,353 Added 22.37%	4,695 Common Stock

MCS

Mark C. Schneyer

EVP, CHIEF FINANCIAL OFFICER

San Diego, CA

Institutional Portfolio Updates

Receive a notification when an Institution or Guru buys or sells ACAD shares.

Notify only if

Value

Insider Trading

Get notified when an Acadia Pharmaceuticals Inc insider buys or sells ACAD shares.

Notify only if

Operation

Value

Type

News

Receive news related to ACADIA PHARMACEUTICALS INC

Track Activities on ACAD

Account